[{"id":"e218cb17-cf88-493f-bf4f-8dea7254ff69","acronym":"","url":"https://clinicaltrials.gov/study/NCT01690624","created_at":"2021-01-18T07:20:15.892Z","updated_at":"2024-07-02T16:37:10.550Z","phase":"Phase 1","brief_title":"BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse","source_id_and_acronym":"NCT01690624","lead_sponsor":"Boehringer Ingelheim","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 836858"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/13/2012","start_date":" 09/13/2012","primary_txt":" Primary completion: 05/21/2018","primary_completion_date":" 05/21/2018","study_txt":" Completion: 05/21/2018","study_completion_date":" 05/21/2018","last_update_posted":"2018-05-23"}]